Janux Therapeutics (JANX) Retained Earnings (2020 - 2025)
Historic Retained Earnings for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to -$319.4 million.
- Janux Therapeutics' Retained Earnings fell 4683.94% to -$319.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$319.4 million, marking a year-over-year decrease of 4683.94%. This contributed to the annual value of -$237.8 million for FY2024, which is 4088.22% down from last year.
- Janux Therapeutics' Retained Earnings amounted to -$319.4 million in Q3 2025, which was down 4683.94% from -$295.1 million recorded in Q2 2025.
- In the past 5 years, Janux Therapeutics' Retained Earnings registered a high of -$23.2 million during Q2 2021, and its lowest value of -$319.4 million during Q3 2025.
- Its 5-year average for Retained Earnings is -$152.9 million, with a median of -$151.2 million in 2023.
- Its Retained Earnings has fluctuated over the past 5 years, first crashed by 23453.44% in 2022, then tumbled by 3029.7% in 2024.
- Over the past 5 years, Janux Therapeutics' Retained Earnings (Quarter) stood at -$47.4 million in 2021, then plummeted by 133.0% to -$110.5 million in 2022, then plummeted by 52.77% to -$168.8 million in 2023, then crashed by 40.88% to -$237.8 million in 2024, then plummeted by 34.35% to -$319.4 million in 2025.
- Its Retained Earnings was -$319.4 million in Q3 2025, compared to -$295.1 million in Q2 2025 and -$261.3 million in Q1 2025.